Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Adjuvant treatment of breast cancer patients with trastuzumab
Authors:ID Matos, Erika (Author)
ID Čufer, Tanja (Author)
Files:.pdf PDF - Presentation file, download (3,80 MB)
MD5: 94EB2103C823D7E3BE4ACD9135729F26
 
Language:English
Typology:1.02 - Review Article
Organization:Logo OI - Institute of Oncology
Abstract:Background. Trastuzumab is a monoclone antibody directed against HER2 receptors that are overexpressed in approximately 20% of breast cancer patients. The present paper presents five clinical trials in which trastuzumabwas applied in breast cancer patients in adjuvant setting. The results of all the trials consistently demonstrate a high efficacy of this target drug in the patients with HER2 positive tumours. So far, no formal guidelines for using trastuzumab in adjuvant setting for breast cancer have been approved. The reasons are many: (i) mean observation time in the studies done so far was considerably short; (ii) the drug was used according to different schedules, (iii) the overall time of treatment with trastuzumab was different in each trial, (iv) late side effects of treatment with trastuzumab are inadequately investigated, and (v) nobody can so far say for sure for which HER2 status patients therapy with trastuzumab is really beneficial. Conclusions. Trastuzumab is definitely very helpful in the treatment of the HER2-positive breast cancer patients that are hormone-independent and of anatomically larger tumours; but, what the absolute benefit of trastuzumab therapy in the treatment of small hormone-dependent tumours is remains a mystery. Incidentally, it must be borne in mind that cardiotoxicity, the well known side effect, may put particularly elderly patients at risk of death, thus beating any treatment advantages down. It has also not been yet resolved at what time it would be most appropriate to start with the therapy with trastuzumab, what would be the optimal duration of the therapy and whether trastuzumab is to be administered concurrently with chemotherapy or immediately after it? What is the optimal treatment duration, one or two yearsor only a few months? In addition there is still a question of optimal HER2 status determination and which HER2 status predicts for trastuzumab benefit. (Abstract truncated at 2000 characters)
Publication status:Published
Publication version:Version of Record
Publication date:01.09.2007
Publisher:Association of Radiology and Oncology
Year of publishing:2007
Number of pages:str. 115-122
Numbering:Vol. 41, no. 3
Source:Ljubljana
PID:20.500.12556/DiRROS-18240 New window
UDC:616-006
ISSN on article:1318-2099
COBISS.SI-ID:23500761 New window
Copyright:by Authors
Note:BSDOCID134804;
Publication date in DiRROS:22.02.2024
Views:755
Downloads:169
Metadata:XML DC-XML DC-RDF
:
MATOS, Erika and ČUFER, Tanja, 2007, Adjuvant treatment of breast cancer patients with trastuzumab. Radiology and oncology [online]. 2007. Vol. 41, no. 3, p. 115–122. [Accessed 29 March 2025]. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=18240
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Title:Dopolnilno zdravljenje bolnic z rakom dojke s transtuzumabom


Back